PMID- 20229159
OWN - NLM
STAT- MEDLINE
DCOM- 20100618
LR  - 20181113
IS  - 1563-258X (Electronic)
IS  - 0043-5341 (Linking)
VI  - 160
IP  - 1-2
DP  - 2010 Jan
TI  - Antithrombotic therapy in patients with coronary artery disease and with type 2 
      diabetes mellitus.
PG  - 30-8
LID - 10.1007/s10354-010-0747-8 [doi]
AB  - Diabetes mellitus (DM) is a life-threatening disease. Patients with DM have a 2- 
      to 4-fold higher risk of developing cardiovascular disease compared to their 
      non-diabetic counterparts. Several drugs are available for the treatment of 
      stable coronary artery disease (CAD) and acute coronary syndrome (ACS). Among 
      oral antiplatelet agents (acetylsalicylic acid, ticlopidine, clopidogrel, and 
      prasugrel), prasugrel has shown the highest efficacy in patients with DM and ACS. 
      The use of glycoprotein IIb-IIIa receptor inhibitors in diabetic subjects with 
      ACS undergoing percutaneous coronary intervention (PCI) reduces adverse clinical 
      events in a greater extent than in non-diabetics. Several direct and indirect 
      antithrombins are recommended for the treatment of ACS such as unfractionated 
      heparin (UFH), enoxaparin, fondaparinux, and bivalirudin. Enoxaparin and 
      bivalirudin have been shown to be superior to UFH among patients with 
      ST-elevation MI (STEMI) and non-ST elevation MI (NSTEMI) also in diabetic 
      subgroup analyses.
FAU - Farhan, Serdar
AU  - Farhan S
AD  - Third Department of Cardiology and Emergency Medicine, Wilhelminen Hospital, 
      Vienna, Austria. serdar.farhan@wienkav.at
FAU - Hochtl, Thomas
AU  - Hochtl T
FAU - Kautzky-Willer, Alexandra
AU  - Kautzky-Willer A
FAU - Wojta, Johann
AU  - Wojta J
FAU - Huber, Kurt
AU  - Huber K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - Austria
TA  - Wien Med Wochenschr
JT  - Wiener medizinische Wochenschrift (1946)
JID - 8708475
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
SB  - IM
MH  - Acute Coronary Syndrome/*blood/*drug therapy
MH  - Angioplasty, Balloon, Coronary
MH  - Combined Modality Therapy
MH  - Coronary Artery Disease/*blood/*drug therapy
MH  - Diabetes Mellitus, Type 2/*blood/*drug therapy
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Practice Guidelines as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
RF  - 86
EDAT- 2010/03/17 06:00
MHDA- 2010/06/19 06:00
CRDT- 2010/03/16 06:00
PHST- 2009/12/15 00:00 [received]
PHST- 2009/12/16 00:00 [accepted]
PHST- 2010/03/16 06:00 [entrez]
PHST- 2010/03/17 06:00 [pubmed]
PHST- 2010/06/19 06:00 [medline]
AID - 10.1007/s10354-010-0747-8 [doi]
PST - ppublish
SO  - Wien Med Wochenschr. 2010 Jan;160(1-2):30-8. doi: 10.1007/s10354-010-0747-8.